Intravitreal bevacizumab: Safety of multiple doses from a single vial for consecutive patients

Hong Kong Medical Journal

Volumn 18, Issue 6, 2012, Pages 488-495

  Ng, D S ^a   Chan, C W ^a   Kwok, A K H ^b   Li, W W T ^b  

^a TUNG WAH EASTERN HOSPITAL   (Hong Kong)

^b HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

Author keywords

Bevacizumab; Endophthalmitis; Intravitreal injections; Ranibizumab; Receptors; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; BACTERIUM ISOLATION; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CENTRAL SEROUS RETINOPATHY; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; CORNEA INJURY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG COST; DRUG INDICATION; DRUG SAFETY; DRUG VIAL; ENDOPHTHALMITIS; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE DRUG DOSE; NEOVASCULAR GLAUCOMA; PACKAGING MATERIAL; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; REVIEW; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISPOSABLE EQUIPMENT; DRUG CONTAMINATION; DRUG COSTS; DRUG PACKAGING; DRUG STORAGE; ENDOPHTHALMITIS; FEMALE; HONG KONG; HOSPITALS, PRIVATE; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872197692     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-335.
2. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelveweek results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.
3. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26:257-261.
4. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339.
5. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular agerelated macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
6. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
7. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24 (5 Suppl):S3-S19.
8. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 2004;24:676-698.
9. Ta CN. Minimizing the risk of endophthalmitis following intravitreous injections. Retina 2004;24:699-705.
10. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90:1344-1349.
11. Jonas JB, Spandau UH, Schlichtenbrede F. Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye (Lond) 2008;22:590-591.
12. Mason JO 3rd, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-567.
13. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395-1399.
14. Mezad-Koursh D, Goldstein M, Heilwail G, Zayit-Soudry S, Loewenstein A, Barak A. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor. Retina 2010;30:1051-1057.
15. Diago T, McCannel CA, Bakri SJ, Pulido JS, Edwards AO, Pach JM. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009;29:601-605.
16. Lee SH, Woo SJ, Park KH, et al. Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab. Eye (Lond) 2010;24:226-232.
17. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87.
18. Yamashiro K, Tsujikawa A, Miyamoto K, et al. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 2010;30:485-490.
19. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145:879-882.
20. Jonas JB, Spandau UH, Rensch F, Von Baltz S, Schlichtenbrede F. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007;23:240-242.
21. Velpandian T, Sharma C, Garg SP, Mandal S, Ghose S. Safety and cost-effectiveness of single dose dispensing of bevacizumab for various retinal pathologies in developing countries. Indian J Ophthalmol 2007;55:488-490.
22. Cavalcante LL, Cavalcante ML, Murray TG, et al. Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clin Ophthalmol 2010;4:519-524.
23. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31:654-661.
24. Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008;115:1911-1915.
25. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond) 2009;23:2187-2193.
26. Civen R, Vugia DJ, Alexander R, et al. Outbreak of Serratia marcescens infections following injection of betamethasone compounded at a community pharmacy. Clin Infect Dis 2006;43:831-837.
27. Pegues DA. Improving and enforcing compounding pharmacy practices to protect patients. Clin Infect Dis 2006;43:838-840.
28. Fink JL 3rd. Application of the Food and Drug Administration's current good manufacturing practices regulations to pharmacy practice: a legal view. Contemp Pharm Pract 1979;2:202-205.
29. ASHP guidelines on quality assurance for pharmacyprepared sterile products. American Society of Health System Pharmacists. Am J Health Syst Pharm 2000;57:1150-1169.
30. Kastango ES, American Society of Health-System Pharmacists (ASHP). Blueprint for implementing USP chapter 797 for compounding sterile preparations. Am J Health Syst Pharm 2005;62:1271-1288.
31. Trissel LA, Gentempo JA, Anderson RW, Lajeunesse JD. Using a medium-fill simulation to evaluate the microbial contamination rate for USP medium-risk-level compounding. Am J Health Syst Pharm 2005;62:285-288.
32. Sheth NK, Post GT, Wisniewski TR, Uttech BV. Multidose vials versus single-dose vials: a study in sterility and costeffectiveness. J Clin Microbiol 1983;17:377-379.
33. Christensen EA, Mordhorst CH, Jepsen OB. Assessment of risk of microbial contamination by use of multidose containers of injectable products. J Hosp Infect 1992; 20:301-304.
34. Rathod M, Saravolatz L, Pohlod D, Whitehouse F, Goldman J. Evaluation of the sterility and stability of insulin from multidose vials used for prolonged periods. Infect Control 1985;6:491-494.
35. Thompson GD, Thompson DF. The effect of the number of withdrawals on the sterility of multidose medication vials. J Clin Pharm Ther 1992;17:61-64.
36. Lin SY, Lay PC, Hughes LF, Bass R. The safety of multi-dose vials in allergy immunotherapy. Otolaryngol Head Neck Surg 2008;139:195-197.
37. Green KA, Mustachi B, Schoer K, Moro D, Blend R, McGeer A. Gadolinium-based MR contrast media: potential for growth of microbial contaminants when single vials are used for multiple patients. AJR Am J Roentgenol 1995;165:669-671.
38. Schubert A, Hyams KC, Longfield RN. Sterility of anesthetic multiple-dose vials after opening. Anesthesiology 1985;62:634-636.
39. Bannerman TL, Rhoden DL, McAllister SK, Miller JM, Wilson LA. The source of coagulase-negative staphylococci in the Endophthalmitis Vitrectomy Study. A comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresis. Arch Ophthalmol 1997;115:357-361.
40. Speaker MG, Milch FA, Shah MK, Eisner W, Kreiswirth BN. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology 1991;98:639-649; discussion 50.
41. Moss JM, Sanislo SR, Ta CN. Antibiotic susceptibility patterns of ocular bacterial flora in patients undergoing intravitreal injections. Ophthalmology 2010;117:2141-2145.
42. Chen YH, Wu PC, Shiea J, Lo LH, Wu YC, Kuo HK. Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months. J Ocul Pharmacol Ther 2009;25:65-69.
43. Ornek K, Karahan ZC, Ergin A, Tekeli A, Tekeli O. Bevacizumab sterility in multiple doses from a single-use vial. Ann Pharmacother 2008;42:1425-1428.
44. Bhavsar AR, Googe JM Jr, Stockdale CR, et al. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol 2009;127:1581-1583.
45. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077.e35.
46. Wykoff CC, Flynn HW Jr, Rosenfeld PJ. Prophylaxis for endophthalmitis following intravitreal injection: antisepsis and antibiotics. Am J Ophthalmol 2011;152:717-719.e2.
47. Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. Arch Ophthalmol 2011;129:1180-1188.
48. Lally DR, Gerstenblith AT, Regillo CD. Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2012;23:182-188.